Bluejay Diagnostics, Inc.(BJDX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Bluejay Diagnostics, Inc. (BJDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BJDX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Bluejay Diagnostics, Inc. reports net income of $-2.3M, free cash flow of $-1.6M. BJDX trades on the Nasdaq exchange and files with the SEC under CIK 1704287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BJDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bluejay Diagnostics, Inc. directly from SEC EDGAR.